In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

Find Insulin Molecule stock video, 4K footage, and other HD footage from iStock. Get higher quality Insulin Molecule content, for less—All of our 4K video clips are the same price as HD. Video Back ...

Eli Lilly has invested heavily into obesity, dominating the landscape—alongside semaglutide maker Novo Nordisk—with its ...

StockNews.com started coverage on shares of vTv Therapeutics (NASDAQ:VTVT – Free Report) in a research report report published on Wednesday. The brokerage issued a sell rating on the biotechnology ...

Shares of Structure Therapeutics Inc. (NASDAQ:GPCR – Get Free Report) have been assigned an average rating of “Buy” from the ...

Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...